FDA Warning Letters and Undeclared Drug Ingredients: What's Still Failing in Supplement Testing

Over the past several years, FDA’s warning letter database has become something of a case study in what happens when finished-product testing gets treated as optional. The agency has repeatedly flagged supplement manufacturers — from small contract packagers to established brands — for products containing pharmaceutical compounds that appear nowhere on the label.

The compounds showing up most frequently aren’t obscure. Sildenafil analogs in “male enhancement” products. SARMs in sports nutrition formulas. Sibutramine in weight loss supplements. These aren’t trace contaminants from sloppy manufacturing. In most cases, they’re intentional adulterants added to make a product work — because without them, the formula often doesn’t.

And that’s what makes this problem so persistent. There’s a financial incentive to cheat, and the testing burden under current law falls almost entirely on the manufacturer’s own good judgment.

Why DSHEA’s Framework Creates This Problem

The Dietary Supplement Health and Education Act of 1994 — DSHEA — fundamentally shifted how supplements are regulated. Unlike pharmaceutical drugs, which require pre-market approval, dietary supplements can reach shelves as long as the manufacturer reasonably believes they’re safe. FDA’s role is largely reactive: the agency investigates after problems surface.

Under 21 CFR Part 111, manufacturers are required to implement Current Good Manufacturing Practices (cGMPs), which include identity testing of every ingredient received and finished-product testing against established specifications. The regulations are real and they have teeth — but enforcement requires FDA to physically inspect facilities, and the agency simply doesn’t have the resources to audit all 50,000+ dietary supplement companies operating in the U.S.

That gap between regulatory intent and enforcement capacity is exactly where adulterated products survive.

The problem is compounded by the supply chain. Many brands don’t manufacture their own products — they work through contract manufacturers or source finished goods from overseas. A Government Accountability Office review of FDA’s supplement oversight noted the agency had limited visibility into the full universe of supplement manufacturers, particularly those operating offshore. When a brand purchases a “proprietary blend” from an overseas supplier, slaps a label on it, and lists it on Amazon, the chances of catching undeclared compounds before they reach consumers are slim without deliberate, targeted testing.

What the Warning Letters Actually Document

FDA’s warning letters aren’t vague. They name products, they name compounds, and they cite the specific 21 CFR Part 111 provisions that were violated. Reading through them is instructive — not just for the violations themselves, but for the pattern they reveal.

The most consistent targets are three product categories: male sexual enhancement products, weight loss supplements, and pre-workout or “energy” formulas. These categories share a common trait: they make physiological claims that are essentially impossible to substantiate without pharmacological activity. A dietary ingredient that genuinely improves erectile function or triggers rapid fat loss at a meaningful scale would, in almost all cases, qualify as a drug under the FD&C Act — not a supplement.

Since FDA launched its publicly searchable database of fraudulent or tainted supplement products, it has catalogued more than 1,000 distinct tainted items. The list grows every year. Stimulants — including compounds structurally related to amphetamine — appear in pre-workout and weight loss products at concentrations high enough to cause cardiovascular events in susceptible individuals. PDE-5 inhibitors (the class that includes sildenafil and tadalafil) show up in male enhancement formulas at doses that would be clinically meaningful for a 70 kg adult male.

This isn’t a quality-control failure in the conventional sense. A conventional QC failure means a product claiming 500 mg of vitamin C actually contains 450 mg, or a botanical ingredient loses potency before its stated expiration date. Those are real compliance problems, but different in kind. What FDA’s warning letters document is products that are functioning exactly as designed — the design just happens to include an undeclared drug.

The Testing Gap: What Standard Panels Miss

Here’s what makes this particularly frustrating from a lab perspective: the testing panel most manufacturers run on finished supplements will not catch these compounds. A typical cGMP compliance test for a sports nutrition product covers label claim verification for declared ingredients, microbial limits per USP <2021> and <2022>, heavy metals, and pesticide residues if the formula includes botanicals. That’s a reasonable baseline. It doesn’t touch adulteration screening.

Detecting undeclared pharmaceutical compounds requires a different toolkit entirely. High-performance liquid chromatography-mass spectrometry (HPLC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) are the methods of choice — capable of identifying target compounds at concentrations below 1 part per million. Broad untargeted screening using high-resolution mass spectrometry can cast a wider net, but it’s significantly more resource-intensive and requires specialized interpretation to distinguish true positives from background noise.

AOAC International has published validated methods for several pharmaceutical adulterants in dietary supplements, including methods for detecting sildenafil analogs and sibutramine in various matrices. FDA’s own laboratories use these and similar methods during market surveillance. The frustrating reality for brands is that there’s no explicit regulatory requirement to run them — which means a large share of the market doesn’t.

As an ISO 17025-accredited laboratory, Qalitex runs adulteration screens as a standard component of finished-product testing for high-risk categories: male enhancement, weight loss, and stimulant-containing sports nutrition products. Our screening panel targets more than 200 pharmaceutical compounds and their structural analogs using LC-MS/MS, because the analogs — slightly modified versions of known banned drugs — are specifically engineered to evade narrower detection methods. We’ve seen enough results over the years to know that products submitted for routine label claim verification sometimes have a more complicated story when the scope is expanded.

The Marketplace Dynamics Making This Worse

Amazon’s third-party seller ecosystem has made it possible to launch a supplement product with minimal overhead and limited quality infrastructure. The supplement category on the platform has grown dramatically — and so has the presence of products from sellers with no traceable manufacturing accountability.

Amazon has implemented compliance requirements in its Dietary Supplements category policy, including mandates for third-party testing from accredited laboratories. But a certificate of analysis that covers identity and heavy metals says nothing about whether the finished product contains undeclared actives. It’s entirely possible to have a legitimate CoA for declared ingredients from an accredited lab and still be selling an adulterated product — because the test commissioned never looked for the right analytes.

FDA’s enforcement actions increasingly reference products sold through online marketplaces. The agency has issued import alerts, mandatory recalls, and warning letters for products sold exclusively through Amazon and similar platforms. The fact that a product is listed on a major marketplace with third-party reviews and polished branding does not mean it has undergone meaningful safety testing. That distinction matters to regulators, and it matters to consumers who have no other way to evaluate what they’re actually buying.

For EU market entry and European regulatory compliance, Care Europe provides expert consulting from Paris.

What Brands Operating in High-Risk Categories Need to Do

If you’re a supplement brand sourcing finished goods from a contract manufacturer — especially in the male enhancement, weight loss, or high-stimulant space — the responsible path is to run a pharmaceutical adulteration screen before you sell a single unit. Not because FDA explicitly requires it. Because if your product causes a cardiovascular event or shows up in an athlete’s doping test, “I didn’t know” is not a defensible position with regulators, plaintiffs’ attorneys, or the public.

Specifically: ask your testing laboratory whether their finished-product panel includes pharmaceutical adulteration screening via LC-MS/MS or high-resolution mass spectrometry. If it’s not standard, request it as a line item. The cost per sample for a 200-compound screen typically runs $300–$600. Compare that to FDA’s estimate that the average dietary supplement recall costs a company approximately $10 million when you account for lost revenue, legal exposure, remediation, and reputational damage. The math is not complicated.

For contract manufacturers, the obligation is more direct. Your 21 CFR Part 111 written specifications for high-risk finished products should explicitly include adulteration testing. If an FDA investigator asks what controls you have to ensure your male enhancement product is free of PDE-5 inhibitors and their analogs, “we verify the label claims” is not going to satisfy them.

And for any brand already operating in these categories: search FDA’s tainted supplements database by manufacturer name, brand, and facility. It’s publicly accessible and updated regularly. If a product from your contract manufacturer — or a direct competitor’s product made in the same facility — has appeared on that list in the past 36 months, that’s a material risk signal that warrants an independent audit of the facility and a comprehensive re-test of your current SKUs.

The warning letters aren’t going to slow down. FDA’s enforcement posture on adulterated supplements has been consistent for more than a decade, and the data suggests it’s intensifying as the agency’s market surveillance capabilities improve. The brands that treat comprehensive adulteration testing as an unnecessary cost will eventually discover what a recall actually costs. The brands that treat it as basic risk management — the same way they treat liability insurance — are the ones that will still be operating five years from now.